Originally Aired: April 30, 2020
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
Cell and gene therapies are redefining the treatments of rare diseases and cancers. Two CAR-T therapies, for instance, rapidly achieved FDA approval in the US and have emerged recently as the new pillars in the treatment of B-cell leukemia. This is a landmark moment for the biopharma industry, with CAR-T therapies expected to dominate the market over the next several years. Yet, despite their meteoric growth, there are several hurdles to overcome when developing efficacious cell and gene therapies, particularly when it comes to the manufacturing of viral vectors—a significant bottleneck in the overall production process. Drawing inspiration from previous successful collaborations with contract development and manufacturing organizations select CDMO union CAR-T engineers are looking to capitalize on the expertise these companies have amassed.
In this GEN webinar, we will hear how GenScript ProBio aids the biopharma industry as it continues to develop and optimize processes for GMP plasmids, lenti, and AAV viral vector manufacturing. Additionally, we will learn how with optimization of manufacturing processes and the tighter relationships between biopharma and CDMOs, the bottlenecks will be overcome step-by-step and mature commercialization for safe, efficacious, and accessible CAR-T therapy.
A live Q&A session followed the presentations, offering the attendee a chance to pose questions to our expert panelists.
Produced with support from:
Yuyuan Dai
Project Manager for Virus Production
GenScript ProBio
